60
novel urinary protein biomarkers for prostate cancer (patent filed)
80%
reduction of unnecessary prostate biopsies
1.4 M
CHF in competitive grants raised for the academic R&D
50 M
men in the US could benefit from our urine test every year
HIGHLY-SENSITIVE, NON-INVASIVE DIAGNOSTICS
INNOVATIVE
IMMUNOASSAYS
ONtrack Biomedical's core technology combines a novel urinary protein biomarker discovery strategy with high-affinity monoclonal antibody generation capability, enabling highly sensitive and specific immunoassays with demonstrated clinical performance in urine
HIGH SENSITIVITY FOR PROSTATE CANCER
Our urine test targets a sensitivity above 95%, meaning the vast majority of patients with prostate cancer will be correctly identified, minimizing the risk of a missed diagnosis
QUALITY OF LIFE
Thanks to a simple urine test, we aim to reduce unnecessary prostate biopsies by up to 80%, sparing patients from an invasive procedure and its side effects
NOVEL BIOMARKERS
ONtrack Biomedical AG has developed an innovative strategy to identify and validate novel protein biomarkers in non-invasive biological samples, applicable to any disease
GET IN TOUCH
ONTRACK Biomedical AG
c/o USZ (Universitätsspital Zurich)
Klinik für Urologie (4th Floor)
Wagistrasse 21
8952 Schlieren
